1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

uniQure Hopeful In Accelerated Approval Potential For Huntington’s Disease

 
• By Alaric DeArment

The biotech announced updated interim Phase I/II data for its gene therapy AMT-130, showing statistically significant improvement compared with an external control.

• Source: Shutterstock

Updated interim data from uniQure N.V.’s Phase I/II study of its gene therapy AMT-130 in Huntington’s disease showed slowing of decline among treated patients compared with an external control, raising the company’s optimism that it may have a pathway to accelerated approval from the US Food and Drug Administration.

The data released 9 July show that patients receiving the high dose of AMT-130 had an 80% slowing of disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 
• By Andrew McConaghie

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Sarepta Voluntarily Stops Shipments Of Elevidys After Previously Refusing FDA Request

 
• By Mandy Jackson

The company had planned to keep its DMD gene therapy available for ambulatory patients, but now says pausing shipments may enable a better working relationship with the US FDA while safety labeling is updated.

More from Advanced Therapies

Sarepta Voluntarily Stops Shipments Of Elevidys After Previously Refusing FDA Request

 
• By Mandy Jackson

The company had planned to keep its DMD gene therapy available for ambulatory patients, but now says pausing shipments may enable a better working relationship with the US FDA while safety labeling is updated.

FDA Asked, Sarepta Refused To Stop Elevidys Shipments After Third Death With Gene Therapy Vector

 
• By Mandy Jackson

Sarepta knew about the death in a Phase I trial of SRP-9004 for LGMD when it recently revealed a restructuring plan, but did not disclose the event. The now-discontinued gene therapy candidate uses the same AAV vector as Elevidys, which has been linked to two DMD patient deaths.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.